Otsuka Holdings Co (OTSKY) AI Stock Analysis

Otsuka Holdings Co

(Other OTC:OTSKY)

Select Model

Rating:81Outperform

Price Target:$44.00▲(17.96% Upside)

Action:reiterated

Date:10/31/26

The score is led by strong earnings growth and an exceptionally conservative balance sheet. Positive technical positioning supports the rating, while weaker recent free-cash-flow conversion and only moderate valuation support limit further upside.

Positive Factors

Revenue Growth and MarginsSteady revenue expansion alongside consistently high gross margins indicates strong economics across Otsuka’s pharmaceutical and consumer businesses. The sharp improvement in operating and net margins since 2023 also suggests greater earnings capacity and supports continued investment in products and growth.

Negative Factors

Declining EPS GrowthNegative EPS growth indicates that per-share earnings have recently weakened despite overall revenue expansion. If this pressure persists, it could limit internal funding for research and commercialization while signaling that improved margins have not translated consistently into stronger earnings for shareholders.

Otsuka Holdings Co (OTSKY) vs. SPDR S&P 500 ETF (SPY)

Market Cap: $40.90B
Dividend Yield: 1.15%
Average Volume (3M): 30.96K
Price to Earnings (P/E): 16.0
Beta (1Y): 0.15
Revenue Growth: 5.41%
EPS Growth: -17.30%
Country: US
Employees: 37,758
Sector: Healthcare
Sector Strength: 51
Industry: Drug Manufacturers - General

Otsuka Holdings Co Business Overview & Revenue Model

Company Description

Otsuka Holdings Co., Ltd. engages in the management of its group companies which are in the pharmaceuticals business. It operates through the following segments: Pharmaceuticals, Nutraceuticals, Consumer Products, and Others. The Pharmaceuticals segm...

How the Company Makes Money

Otsuka Holdings makes money primarily by selling products through its operating subsidiaries across two main segments: 1) Pharmaceuticals (prescription medicines) - Revenue model: The company generates revenue from the sale of prescription drugs to h...

Otsuka Holdings Co Earnings Call Summary

Earnings Call Date:Jul 31, 2024(Q2-2024)|% Change Since:47.71%|Next Earnings Date:Feb 11, 2027

Earnings Call SentimentPositive

The earnings call presented a strong overall performance in both pharmaceutical and nutraceutical segments with significant revenue and profit growth, and positive strategic expansions such as the acquisition for drug discovery. However, there were challenges such as impairment losses and increased SG&A expenses.

Positive Updates

Significant Revenue and Profit Growth

Revenue increased by 17.0% to JPY 1,108.9 billion, and business profit grew by 37.8% to JPY 213.6 billion year-on-year, highlighting strong performance in pharmaceutical and nutraceutical segments.

Negative Updates

Impairment Loss Impact

Operating profit was impacted by an impairment loss on AVP-786, which led to strategic discontinuation of its development.

Company Guidance

During the Q2 2024 earnings call for 4578.T, significant financial growth was highlighted, with revenue increasing by 17.0% to JPY 1,108.9 billion and business profit rising by 37.8% to JPY 213.6 billion year-on-year, driven by strong performance in pharmaceutical and nutraceutical segments. Despite an impairment loss on AVP-786 affecting operating profit, net profit climbed by 5.1% due to finance income. The pharmaceutical business saw revenue increase by 17.9% to JPY 766.7 billion, bolstered by products like ABILIFY MAINTENA and JYNARQUE, while LONSURF achieved significant gains through colorectal cancer treatment guidelines endorsements. Nutraceuticals experienced over 20% growth, with revenue reaching JPY 271.8 billion, fueled by a 56.9% rise in the For Women's Health category. The company revised its full-year forecast, raising revenue expectations by JPY 175 billion to JPY 2,315 billion and business profit projections by JPY 60 billion to JPY 390 billion, aiming to maintain momentum through strategic investments and addressing social issues.

Otsuka Holdings Co Financial Statement Overview

Summary

Strong financial performance, combining excellent balance-sheet strength and improving earnings with positive but somewhat weaker free-cash-flow conversion.

Income Statement

91Very Positive

Balance Sheet

94Very Positive

Cash Flow

75Positive

Financial statement breakdown
Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	2.73T	2.59T	2.33T	2.02T	1.74T	1.50T
Gross Profit	1.96T	1.86T	1.67T	1.41T	1.17T	1.00T
EBITDA	611.24B	554.23B	452.62B	246.96B	279.83B	231.43B
Net Income	392.13B	380.76B	343.12B	121.62B	133.91B	125.46B
Balance Sheet
Total Assets	4.32T	4.20T	3.74T	3.36T	3.10T	2.82T
Cash, Cash Equivalents and Short-Term Investments	505.43B	569.00B	458.08B	529.40B	489.12B	430.76B
Total Debt	191.49B	227.97B	189.38B	214.19B	194.16B	212.45B
Total Liabilities	1.04T	1.10T	961.09B	924.93B	840.17B	775.73B
Stockholders Equity	3.22T	3.04T	2.73T	2.39T	2.23T	2.01T
Cash Flow
Free Cash Flow	319.24B	331.04B	225.28B	168.56B	104.06B	115.71B
Operating Cash Flow	424.53B	423.14B	354.64B	283.23B	211.85B	228.86B
Investing Cash Flow	-261.24B	-169.42B	-265.79B	-190.54B	-81.58B	-95.29B
Financing Cash Flow	-198.82B	-144.00B	-189.37B	-60.26B	-95.47B	-95.84B

Otsuka Holdings Co Technical Analysis

Technical Analysis SentimentPositive

Last Price37.30

Price Trends

50DMA37.39Positive

100DMA36.22Positive

200DMA34.77Positive

Market Momentum

MACD0.59Positive

RSI51.64Neutral

STOCH13.52Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For OTSKY, the sentiment is Positive. The current price of 37.30 is below the 20-day moving average (MA) of 38.00, below the 50-day MA of 37.39, and above the 200-day MA of 34.77, indicating a bullish trend. The MACD of 0.59 indicates Positive momentum. The RSI at 51.64 is Neutral, neither overbought nor oversold. The STOCH value of 13.52 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for OTSKY.

Otsuka Holdings Co Peers Comparison

Overall Rating

UnderperformOutperform

Sector (51)

Financial Indicators

OTSKY against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
SNY	83Outperform	$106.98B	24.66	5.52%	5.31%	23.68%	-30.90%
OTSKY	81Outperform	$39.95B	15.98	12.31%	1.15%	5.41%	-17.30%
PFE	74Outperform	$173.95B	40.52	4.89%	5.61%	-0.21%	-59.71%
NVS	72Outperform	$298.74B	30.87	24.24%	2.93%	1.64%	-28.72%
JNJ	70Outperform	$657.68B	41.02	19.55%	1.95%	7.81%	-35.95%
GSK	67Neutral	$99.66B	16.89	24.64%	3.70%	6.93%	-18.14%
Sector *	51Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%

* Healthcare Sector Average

Performance Comparison

OTSKY and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
OTSKY	Otsuka Holdings Co., Ltd. (OTSKY)	37.28	9.56	34.50%
GSK	GlaxoSmithKline	49.13	3.89	8.60%
JNJ	Johnson & Johnson	270.56	87.82	48.06%
NVS	Novartis AG	161.52	38.91	31.74%
PFE	Pfizer Inc	30.67	7.96	35.07%
SNY	Sanofi SA	45.55	-1.68	-3.55%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Oct 31, 2026

Otsuka Holdings Co AI Stock Analysis